198 related articles for article (PubMed ID: 16728576)
1. Expression of tpo mRNA in thyroid tumors: quantitative PCR analysis and correlation with alterations of ret, Braf , ras and pax8 genes.
Di Cristofaro J; Silvy M; Lanteaume A; Marcy M; Carayon P; De Micco C
Endocr Relat Cancer; 2006 Jun; 13(2):485-95. PubMed ID: 16728576
[TBL] [Abstract][Full Text] [Related]
2. PAX8-PPARgamma rearrangement is frequently detected in the follicular variant of papillary thyroid carcinoma.
Castro P; Rebocho AP; Soares RJ; Magalhães J; Roque L; Trovisco V; Vieira de Castro I; Cardoso-de-Oliveira M; Fonseca E; Soares P; Sobrinho-Simões M
J Clin Endocrinol Metab; 2006 Jan; 91(1):213-20. PubMed ID: 16219715
[TBL] [Abstract][Full Text] [Related]
3. Concomitant RAS, RET/PTC, or BRAF mutations in advanced stage of papillary thyroid carcinoma.
Zou M; Baitei EY; Alzahrani AS; BinHumaid FS; Alkhafaji D; Al-Rijjal RA; Meyer BF; Shi Y
Thyroid; 2014 Aug; 24(8):1256-66. PubMed ID: 24798740
[TBL] [Abstract][Full Text] [Related]
4. Trisomy 17 as a marker for a subset of noninvasive thyroid nodules with focal features of papillary carcinoma: cytogenetic and molecular analysis of 62 cases and correlation with histological findings.
Frau DV; Lai ML; Caria P; Dettori T; Coni P; Faa G; Morandi L; Tallini G; Vanni R
J Clin Endocrinol Metab; 2008 Jan; 93(1):177-81. PubMed ID: 17956956
[TBL] [Abstract][Full Text] [Related]
5. Laser capture microdissection is a valuable tool in the preoperative molecular screening of follicular lesions of the thyroid: an institutional experience.
Bongiovanni M; Molinari F; Eszlinger M; Paschke R; Barizzi J; Merlo E; Giovanella L; Fasolini F; Cattaneo F; Ramelli F; Mazzucchelli L; Frattini M
Cytopathology; 2015 Oct; 26(5):288-96. PubMed ID: 25487739
[TBL] [Abstract][Full Text] [Related]
6. BRAFV600E mutation, but not RET/PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer.
Romei C; Ciampi R; Faviana P; Agate L; Molinaro E; Bottici V; Basolo F; Miccoli P; Pacini F; Pinchera A; Elisei R
Endocr Relat Cancer; 2008 Jun; 15(2):511-20. PubMed ID: 18509003
[TBL] [Abstract][Full Text] [Related]
7. From nodule to differentiated thyroid carcinoma: contributions of molecular analysis in 2012.
Albarel F; Conte-Devolx B; Oliver C
Ann Endocrinol (Paris); 2012 Jun; 73(3):155-64. PubMed ID: 22503804
[TBL] [Abstract][Full Text] [Related]
8. BRAF V600E and decreased NIS and TPO expression are associated with aggressiveness of a subgroup of papillary thyroid microcarcinoma.
Bastos AU; Oler G; Nozima BH; Moysés RA; Cerutti JM
Eur J Endocrinol; 2015 Oct; 173(4):525-40. PubMed ID: 26338373
[TBL] [Abstract][Full Text] [Related]
9. Impact of molecular screening for point mutations and rearrangements in routine air-dried fine-needle aspiration samples of thyroid nodules.
Eszlinger M; Krogdahl A; Münz S; Rehfeld C; Precht Jensen EM; Ferraz C; Bösenberg E; Drieschner N; Scholz M; Hegedüs L; Paschke R
Thyroid; 2014 Feb; 24(2):305-13. PubMed ID: 23837487
[TBL] [Abstract][Full Text] [Related]
10. Comparative genomic hybridization, BRAF, RAS, RET, and oligo-array analysis in aneuploid papillary thyroid carcinomas.
Rodrigues R; Roque L; Espadinha C; Pinto A; Domingues R; Dinis J; Catarino A; Pereira T; Leite V
Oncol Rep; 2007 Oct; 18(4):917-26. PubMed ID: 17786355
[TBL] [Abstract][Full Text] [Related]
11. RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma.
Nikiforova MN; Lynch RA; Biddinger PW; Alexander EK; Dorn GW; Tallini G; Kroll TG; Nikiforov YE
J Clin Endocrinol Metab; 2003 May; 88(5):2318-26. PubMed ID: 12727991
[TBL] [Abstract][Full Text] [Related]
12. PAX8 and peroxisome proliferator-activated receptor gamma 1 gene expression status in benign and malignant thyroid tissues.
Lacroix L; Mian C; Barrier T; Talbot M; Caillou B; Schlumberger M; Bidart JM
Eur J Endocrinol; 2004 Sep; 151(3):367-74. PubMed ID: 15362967
[TBL] [Abstract][Full Text] [Related]
13. BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism.
Durante C; Puxeddu E; Ferretti E; Morisi R; Moretti S; Bruno R; Barbi F; Avenia N; Scipioni A; Verrienti A; Tosi E; Cavaliere A; Gulino A; Filetti S; Russo D
J Clin Endocrinol Metab; 2007 Jul; 92(7):2840-3. PubMed ID: 17488796
[TBL] [Abstract][Full Text] [Related]
14. Detection of PAX8/PPARG and RET/PTC rearrangements is feasible in routine air-dried fine needle aspiration smears.
Ferraz C; Rehfeld C; Krogdahl A; Precht Jensen EM; Bösenberg E; Narz F; Hegedüs L; Paschke R; Eszlinger M
Thyroid; 2012 Oct; 22(10):1025-30. PubMed ID: 23025542
[TBL] [Abstract][Full Text] [Related]
15. Molecular genotyping of papillary thyroid carcinoma follicular variant according to its histological subtypes (encapsulated vs infiltrative) reveals distinct BRAF and RAS mutation patterns.
Rivera M; Ricarte-Filho J; Knauf J; Shaha A; Tuttle M; Fagin JA; Ghossein RA
Mod Pathol; 2010 Sep; 23(9):1191-200. PubMed ID: 20526288
[TBL] [Abstract][Full Text] [Related]
16. Expression of PAX8-PPAR gamma 1 rearrangements in both follicular thyroid carcinomas and adenomas.
Marques AR; Espadinha C; Catarino AL; Moniz S; Pereira T; Sobrinho LG; Leite V
J Clin Endocrinol Metab; 2002 Aug; 87(8):3947-52. PubMed ID: 12161538
[TBL] [Abstract][Full Text] [Related]
17. Molecular analysis of thyroid tumors.
Bhaijee F; Nikiforov YE
Endocr Pathol; 2011 Sep; 22(3):126-33. PubMed ID: 21739166
[TBL] [Abstract][Full Text] [Related]
18. Molecular profile and clinical-pathologic features of the follicular variant of papillary thyroid carcinoma. An unusually high prevalence of ras mutations.
Zhu Z; Gandhi M; Nikiforova MN; Fischer AH; Nikiforov YE
Am J Clin Pathol; 2003 Jul; 120(1):71-7. PubMed ID: 12866375
[TBL] [Abstract][Full Text] [Related]
19. Aneuploidy and RAS mutations are mutually exclusive events in the development of well-differentiated thyroid follicular tumours.
Banito A; Pinto AE; Espadinha C; Marques AR; Leite V
Clin Endocrinol (Oxf); 2007 Nov; 67(5):706-11. PubMed ID: 17651453
[TBL] [Abstract][Full Text] [Related]
20. The Ras effector NORE1A is suppressed in follicular thyroid carcinomas with a PAX8-PPARgamma fusion.
Foukakis T; Au AY; Wallin G; Geli J; Forsberg L; Clifton-Bligh R; Robinson BG; Lui WO; Zedenius J; Larsson C
J Clin Endocrinol Metab; 2006 Mar; 91(3):1143-9. PubMed ID: 16352687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]